All News

The FDA approved ceftobiprole medocaril sodium for injection (Zevtera) in April 2024.

Jon Minkin, enterprise account executive at NimbleRx, shared how his company can help independent pharmacies unlock revenue opportunities.

Erin Albert, vice president of pharmacy relations and chief privacy officer at Mark Cuban Cost Plus Drug Company, PBC, discussed drug pricing and what her company is doing to revolutionize transparency.

In case you missed it, this week we had stories about medication-related disaster preparedness, COVID-19 and cardiovascular risks, legal battles over inflated insulin prices, and more.

Check out important updates from the FDA for the week of October 7.

Marstacimab-hncq is the first non-factor and once-weekly treatment available for patients with hemophilia B and promises to reduce the burden of care.

A study published in Arteriosclerosis, Thrombosis, and Vascular Biology found the risk of major adverse cardiac events was higher in patients hospitalized with COVID-19.

The approval is supported by results from phase 3 multi-regional clinical trials conducted in patients with plaque psoriasis.

Recent research on vitamin D supplementation and respiratory tract infections can help guide pharmacists in counseling patients.

Guselkumab is currently approved by the FDA to treat adults with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, and adults with moderately to severely active ulcerative colitis.

Researchers analyzed the potential role of nonphysician health care providers to provide vaccine services outside of traditional health care settings.

The therapy’s Prescription Drug User Fee Act date has been set for July 26, 2025.

This year’s annual meeting of the American College of Chest Physicians featured more than 300 educational sessions, insights from over 600 faculty members, and 29.5 hours of CE credits.

Two posters presented at the annual meeting of the American College of Chest Physicians, CHEST 2024, offered insights into the accurate diagnosis and appropriate treatment of ACOS.

Research presented at CHEST 2024 examined outcomes of COVID-19 on patients with alcoholic liver disease, cirrhosis, and non-alcohol steatohepatitis.

Emily Endres, BSPS, vice president of pharmacy at PQS by Innovaccer, provides insights into the industry’s next phase.

On October 3,2024, Texas Attorney General Ken Paxton issued the lawsuit, which involves Eli Lilly, Express Scripts, CVS Pharmacy, and other pharmaceutical entities.

Research Presented at CHEST 2024 reported on how mepolizumab can improve asthma control, and reduce exacerbations of concurrent asthma and COPD.

Current rules governing lawsuits must be revisited to strike a balance between legitimate and frivolous legal actions against health care providers.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Anthony Minniti of Bell Pharmacy in Camden, New Jersey, discussed pharmacy in his community and the challenges that come with it.

Adherence interventions and comprehensive reviews can reduce health care costs, boost revenue, and improve patient outcomes.

The Healgen Rapid Check COVID-19/Flu A&B Antigen Test is the first at-home test to be granted marketing authorization using a traditional premarket review pathway.

The 70-plus-page lawsuit is directed at Express Scripts for its dealings with drug manufacturers in fueling the US opioid crisis.

Florida-based pharmacist Brad Phillips, PharmD, BCACP, speaks to the importance of pre-planning, emergency refills, medication storage, and post-storm safety measures to ensure medication security during hurricanes.

Medication therapy management can change the trajectory of patient health outcomes. Here is how pharmacists can ensure adherence and compensation.

Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and COPD.

Research presented at CHEST 2024 outlined the heart failure risks associated with COVID-19 infection and emphasized the importance of vaccination to prevent adverse outcomes.

A roundtable session discussed the real-world implications of applying DIR fees at the point of sale rather than through retroactive clawback.